A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies

Authors :: B. Peng
Margaret Dugan
Peter Atadja
Richard Stone
Heike Pfeifer
Pieter Sonneveld
Bob Löwenberg
Jeffrey W. Scott
Daniel J. DeAngelo
Oliver G. Ottmann
Source :: Journal of Clinical Oncology. 22:3024-3024
Publication Year :: 2004
Publisher :: American Society of Clinical Oncology (ASCO), 2004.
Abstract: 3024 Background: LAQ824 is a novel cinnamic acid hydroxamate that inhibits HDAC activity, IC50 of 0.03 μM, and acetylates hsp90 thereby inducing proteosomal degradation of Bcr-Abl and her-2. Method...

Subjects :: Cancer Research
biology
business.industry
medicine.drug_class
Histone deacetylase inhibitor
Pharmacology
Hsp90
Cinnamic acid
chemistry.chemical_compound
Oncology
Pharmacokinetics
chemistry
hemic and lymphatic diseases
Pharmacodynamics
biology.protein
Medicine
In patient
business
IC50

Full Text Access

Tools